VLON vs. WHWK, VIRI, ATNM, PYRGF, OSTX, EGRX, AADI, NBRV, ELYM, and HILS
Should you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Whitehawk Therapeutics (WHWK), Virios Therapeutics (VIRI), Actinium Pharmaceuticals (ATNM), PyroGenesis Canada (PYRGF), OS Therapies (OSTX), Eagle Pharmaceuticals (EGRX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Eliem Therapeutics (ELYM), and Hillstream BioPharma (HILS).
Vallon Pharmaceuticals vs. Its Competitors
Whitehawk Therapeutics (NASDAQ:WHWK) and Vallon Pharmaceuticals (NASDAQ:VLON) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.
Vallon Pharmaceuticals has lower revenue, but higher earnings than Whitehawk Therapeutics. Vallon Pharmaceuticals is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Whitehawk Therapeutics has a net margin of 99.42% compared to Vallon Pharmaceuticals' net margin of 0.00%. Whitehawk Therapeutics' return on equity of -56.73% beat Vallon Pharmaceuticals' return on equity.
52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Vallon Pharmaceuticals shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by company insiders. Comparatively, 37.3% of Vallon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Whitehawk Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Vallon Pharmaceuticals has a beta of -1.14, suggesting that its stock price is 214% less volatile than the S&P 500.
In the previous week, Whitehawk Therapeutics had 2 more articles in the media than Vallon Pharmaceuticals. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 0 mentions for Vallon Pharmaceuticals. Whitehawk Therapeutics' average media sentiment score of 0.93 beat Vallon Pharmaceuticals' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.
Summary
Whitehawk Therapeutics beats Vallon Pharmaceuticals on 11 of the 13 factors compared between the two stocks.
Get Vallon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VLON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vallon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VLON) was last updated on 7/26/2025 by MarketBeat.com Staff
